GeoVax Labs Inc. announced the expansion of its preventative HIV/AIDS vaccine development program in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) and the HIV Vaccine Trials Network (HVTN), according to a GeoVax statement. HVTN plans to clinically test the vaccine, which consists of a recombinant DNA vaccine that co-expresses human granulocyte-macrophage colony stimulating factor (GM-CSF) and non-infectious HIV virus-like particles. This builds on the DNA/MVA vaccine that's currently in Phase 2a clinical testing through HVTN. The GM-CSF–enhanced vaccine has shown to protect against infection 70 percent of the time in non-human primates.

To read the GeoVax statement, click here.